Yuzu | $35,000,000 | (Apr 7, 2026)
Moonbounce | $12,000,000 | (Apr 7, 2026)
Insight Health AI, Inc. | $11,000,000 | (Apr 7, 2026)
Aulos Bioscience
United States
- Larkspur, California
- 01/08/2023
- Series A
- $20,000,000
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems towards killing tumor cells.
Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors.
The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
- Industry Biotechnology Research
- Website https://aulosbio.com/
- LinkedIn https://www.linkedin.com/company/aulos-bioscience/
Ridge AI | $2,600,000 | (Apr 7, 2026)
NeuBird AI | $19,300,000 | (Apr 7, 2026)
Stipple Bio | $100,000,000 | (Apr 7, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)